These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25903343)

  • 1. Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.
    Wang Q; Bi W; Zhu X; Li H; Qi Q; Yu F; Lu L; Jiang S
    J Virol; 2015 Jul; 89(13):6960-4. PubMed ID: 25903343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.
    Rubio AA; Filsinger Interrante MV; Bell BN; Brown CL; Bruun TUJ; LaBranche CC; Montefiori DC; Kim PS
    J Virol; 2021 Jul; 95(15):e0235020. PubMed ID: 33980592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
    Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
    Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
    Zhou N; Fan L; Ho HT; Nowicka-Sans B; Sun Y; Zhu Y; Hu Y; McAuliffe B; Rose B; Fang H; Wang T; Kadow J; Krystal M; Alexander L; Colonno R; Lin PF
    Virology; 2010 Jul; 402(2):256-61. PubMed ID: 20400170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.
    Hrin R; Montgomery DL; Wang F; Condra JH; An Z; Strohl WR; Bianchi E; Pessi A; Joyce JG; Wang YJ
    AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1537-44. PubMed ID: 19102685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.
    Wu C; Raheem IT; Nahas DD; Citron M; Kim PS; Montefiori DC; Ottinger EA; Hepler RW; Hrin R; Patel SB; Soisson SM; Joyce JG
    Proc Natl Acad Sci U S A; 2024 May; 121(22):e2317230121. PubMed ID: 38768344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.
    Dawood R; Benjelloun F; Pin JJ; Kone A; Chanut B; Jospin F; Lucht F; Verrier B; Moog C; Genin C; Paul S
    AIDS; 2013 Mar; 27(5):717-30. PubMed ID: 23719346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
    Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
    Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F(ab')2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket.
    Lu L; Wei M; Chen Y; Xiong W; Yu F; Qi Z; Jiang S; Pan C
    Microbes Infect; 2013 Nov; 15(13):887-94. PubMed ID: 24141089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
    J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
    Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
    J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.